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Abstract
Background
We evaluated plasma samples HIV-infected individuals with different phenotypic profile
among five HIV-infected elite controllers and five rapid progressors after recent HIV infection
and one year later and from 10 individuals subjected to antiretroviral therapy, five of whom
were immunological non-responders (INR), before and after one year of antiretroviral treat-
ment compared to 175 samples from HIV-negative patients. A targeted quantitative tandem
mass spectrometry metabolomics approach was used in order to determine plasma meta-
bolomics biosignature that may relate to HIV infection, pace of HIV disease progression,
and immunological response to treatment.
Results
Twenty-five unique metabolites were identified, including five metabolites that could distin-
guish rapid progressors and INRs at baseline. Severe deregulation in acylcarnitine and
sphingomyelin metabolism compatible with mitochondrial deficiencies was observed. β-oxi-
dation and sphingosine-1-phosphate-phosphatase-1 activity were down-regulated, whereas
acyl-alkyl-containing phosphatidylcholines and alkylglyceronephosphate synthase levels
were elevated in INRs. Evidence that elite controllers harbor an inborn error of metabolism
(late-onset multiple acyl-coenzyme A dehydrogenase deficiency [MADD]) was detected.
Conclusions
Blood-based markers from metabolomics show a very high accuracy of discriminating HIV
infection between varieties of controls and have the ability to predict rapid disease progres-
sion or poor antiretroviral immunological response. These metabolites can be used as
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Background
The average period for HIV progression from acute infection to AIDS is 8 years[1]. However,
elite controllers are able to naturally control HIV-1 replication and maintain adequate CD4+
T cell levels[2], while rapid progressors may evolve to AIDS in a period as short as 2 years[1].
Furthermore, 30% of the HIV-infected population, referred to as immunological non-
responders (INR), fail to increase CD4+ T cell counts by at least 30% despite being treated
with antiretrovirals and achieving viral suppression for a year or more[3].
Metabolomics, the unbiased identification and quantification of small molecules in biologi-
cal fluids[4], can serve as a path to the understanding of biochemical state of an organism and
aid in the discovery of biomarkers. Furthermore, quantitative measurement by mass spectros-
copy of specific metabolic products in plasma, urine or cells from cases compared to those
from controls has begun to reveal critical differences in the products of diseased versus normal
tissues for a wide variety of conditions, including prostate cancer [5], colon and stomach can-
cer [6], and Parkinson’s disease [7], and HIV. In this regard, profound misbalanced functions
related to energy, protein, lipid and glucose metabolism have been reported in HIV-infected
individuals since recognition of the disease and introduction of ART [8–12]. Increases in
metabolism are reported to be present already during asymptomatic periods and can reach
even higher levels during opportunistic infections[10–13]. Very recently, the metabolic path-
way related to the transport of the amino acid alanine was proved to be important for T cell
activation; Indeed, impairments of alanine transport in CD4 T cells might contribute to HIV-1
pathogenesis through modulation of virus production, weakening of the adaptive immune
response as well as enhancement of CD4 T-cell loss [13]. In the current study, we hypothesized
that distinct individual phenotype among HIV-infected individuals will display distinct meta-
bolomics profile.
The purpose of this study was to identify metabolites that are unique to HIV-infected indi-
viduals and to identify biomarkers that relates to HIV natural evolution and biomarkers that
relate to immunological response to antiretroviral treatment using a targeted quantitative tan-
dem mass spectrometry (MS/MS) metabolomics approach in order to gain insights into the
mechanisms of HIV.
Methods
We analyzed four panels of previously unthawed frozen plasma samples from HIV-infected
individuals prospectively every 3 months using a targeted quantitative tandem mass spectrom-
etry (MS/MS) metabolomics approach. Twenty patients were selected from a HIV recent infec-
tion cohort in Sao Paulo, Brazil. Individuals were identified as recent HIV infections using the
Serologic Testing Algorithm for Recent HIV Seroconversion[14]. Written Informed consent
has been obtained from all participants and Institutional Review Board (Comitê de E´tica em
Pesquisa da Universidade Federal de São Paulo / Escola Paulista de Medicina–CEP/UNIFE-
SP-EPM) approved study (#1586/11).
All patients were randomly selected according to their phenotype (elite controllers or rapid
progressors) or their response to antiretroviral treatment. Elite controllers were defined as hav-
ing a viral load below 400 copies/mL plasma after recent infection for a period of at least 2
years, and T+ CD4 cell counts with a positive slope using linear regression (Panel A in S1 Fig).
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Rapid progressors were defined as having higher viral load positive slopes and a faster decrease
in CD4+ T cell counts using linear regression (Panel B in S1 Fig). Selected patients were not
using any concurrent medications or supplements, did not have any detected comorbidities,
and did not have any laboratory abnormalities related to blood cell counts, glycose, liver, kid-
ney or pancreatic measurements.
Group A comprised samples from five elite controllers collected during recent HIV infec-
tion (Panel A1 in S1 Fig) and after one year of follow-up (Panel A2 in S1 Fig). Group B (in S1
Fig) used the same strategy for 5 HIV-1 rapid progressors, with samples collected during
recent HIV infection (Panel B1 in S1 Fig) and after one year of follow-up (Panel B2 in S1 Fig).
Group C consisted of five patients who underwent antiretroviral therapy after reaching CD4
+ T cell counts below 350 cells/ μ L, and in whom viral loads reached levels below detection
limits of 50 copies/mL and CD4+ T cell counts increased to at least 30% from baseline upon
treatment. Group D used the same strategy for five INR. Antiretroviral treatment on groups C
and D was homogeneously comprised of an association of fixed dose combination of zidovu-
dine and 3TC administered BID, and a QD dose of Efavirenz, according to the local Brazilian
guidelines at that time. We analyzed samples from patients who experienced different paces of
disease progression (Group A versus Group B) compared to patients who were either viremic
(Groups B, C1 and D1), naturally aviremic (Group A), aviremic upon antiretroviral treatment
(Group C2 and D2), or presented a distinct immunological response upon treatment (groups
C versus D). The clinical characteristics of the subjects are depicted in Table A in S1 File.
All metabolomics data were used as received from Biocrates. Samples were blindly ana-
lyzed, and no data points were removed. The experimental metabolomics measurement tech-
nique is described in detail by US patent 2007/0004044 (accessible online at Free Patents
Online). The company had no access to phenotype information that would have permitted
any data pre-filtering other than objective quality control for measurement errors based on
internal controls and duplicates.
A summary of the method can be found in [15–17] and a comprehensive overview of the
field and the related technologies is given in the review paper by Wenk[18]. Briefly, a targeted
profiling scheme was used to quantitatively screen for known small molecule metabolites
using multiple reaction monitoring, neutral loss and precursor ion scans. Quantification of the
metabolites of the biological sample was achieved by referencing to appropriate internal stan-
dards. The method is in conformance with 21CFR (Code of Federal Regulations) Part 11,
which implies proof of reproducibility within a given error range. The concentrations of all
analyzed metabolites were reported in μM and the results were compared to tumor response
rates and tumor intrinsic subtypes. This method has been used in different academic and
industrial applications[19].
The metabolite panel is composed of 186 different metabolites: 40 acylcarnitines, 19 protei-
nogenic amino acids, ornithine and citrulline, 19 biogenic amines, the sum of hexoses, 76
phosphatidylcholines, 14 lyso-phosphatidylcholines and 15 sphingomyelins.
Glycerophospholipids are further differentiated with respect to the presence of ester (a) and
ether (e) bonds in the glycerol moiety, where two letters (aa = diacyl, ae = acyl-alkyl, ee = dia-
lkyl) denote that two glycerol positions are bound to a fatty acid residue, while a single letter
(a = acyl or e = alkyl) indicates the presence of a single fatty acid residue.
Lipid side chain composition is abbreviated as Cx:y, where x denotes the number of carbons
in the side chain and y the number of double bonds. For example, ‘‘PC ae C38:1” denotes a
plasmalogen/plasminogen phosphatidylcholine with 38 carbons in the two fatty acid side
chains and a single double bond in one of them.
In addition to individual quantification, groups of metabolites related to specific functions
were analyzed. Groups of AAs were computed by summing the levels of AA belonging to
HIV Plasma Metabolomics Biosignature
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certain families or chemical structures depending on their functions such as essential AA,
non-essential AA, glucogenic AA, total AA, branched-chain AA, Aromatic AA, glutaminolysis
AA (Ala+Asp+Glu). Groups of ACs, important to evaluate mitochondrial function, were also
computed by summing (Total AC, C2+C3, C16+C18, C16+C18:1, C16-OH+C18:1-OH).
Groups of lipids, important to evaluate lipid metabolism, were also analyzed by summing
(total LPCs, total PC aa, total PC ae, total SMs, total lipids) (Table B in S1 File).
Proportions among metabolites such as the Fischer’s ratio, a clinical indicator of liver
metabolism and function [13] or the clinical indicators of isovaleric acidemia, tyrosinemia and
urea cycle deficiency were calculated, as the ratios of branched chain amino acid (leucine+iso-
leucine+valine) to aromatic amino acid (tyrosine+phenylalanine), valerylcarnitine to butyryl-
carnitine (C5/C4), tyrosine to serine (Tyr/Ser) respectively. A complete list of ratios reflecting
enzyme activities of specific metabolic pathways have been previously described. [5]
To unambiguously identify and quantify metabolites, stable isotope dilution-multiple reac-
tion monitoring mass spectrometry was performed using targeted quantitative metabolomics
platforms at Biocrates (Life Sciences AG, Innsbruck, Austria) in 215 plasma samples; 40 from
HIV patients and 175 from controls (58 healthy volunteers, 53 colon cancer patients and 64
breast cancer patients, because the metabolic profile of activated inflammatory cells is similar
to tumor cells[20]).Multivariate profile-wide predictive models were constructed using Cross
Validated Partial Least Squares Discriminant Analysis (PLS-DA). For each metabolite, the data
were mean centered and scaled to unit variance[21]. Associations between the 28 blood metab-
olites and HIV-1 infection were assessed using Pearson’s r analysis. We do not report in this
study the metabolite profiles that are common between the study group and control groups,
but only metabolites that were unique to HIV infection.
The number of latent variables in each model was selected using stratified 10-fold cross vali-
dation and calculating associated R2 and Q2 statistics. The predictors were subjected to permu-
tation testing. The results (p<5e-04) confirmed our PLS-DA analysis and revealed a clear
discrimination between plasma samples from 40 samples from 20 HIV-infected individuals and
175 HIV negative counterparts employing PLS-DA and permutation testing analysis (p<5e-04
after 2000 permutations) (S2 Fig). Receiver operating characteristic (ROC) curves were deter-
mined during training and validation sets such that an accurate assessment of discriminatory
ability could be made confirming the existence of highly discriminative metabolites.
Training cases were used for marker discovery and to identify any clinical variable that
might be associated with a response by logistic regression analysis. Quantification of metabo-
lite concentrations and quality control assessment was performed with the MetIQ software
package (BIOCRATES Life Sciences AG, Innsbruck, Austria). Internal standards served as the
reference for the metabolite concentration calculations. An Excel file was then exported, which
contained sample names, metabolite names and metabolite concentration with the unit
of μmol/L of plasma.
For metabolomic data analysis, log-transformation was applied to all quantified metabolites
to normalize the concentration distributions. The data were uploaded into the web-based ana-
lytical pipeline MetaboAnalyst 2.0 (MetaboAnalyst) and normalized using MetaboAnalyst
normalization protocols[22] for uni- and multivariate analysis, high dimensional feature selec-
tion, clustering and supervised classification, functional enrichment and metabolic pathway
analysis. Significantly altered metabolites were defined by a T Test analysis with p-value <0.05
and FDR0.05.
The data were also imported to ROCCET (ROC Curve Explorer & Tester; available at
ROCCET) for the generation of uni- and multivariate Receiver Operating Characteristic
(ROC) curves obtained through Support Vector Machine (SVM), Partial Least Squares-Dis-
criminant Analysis (PLS-DA) and Random Forests.
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Curves were generated by Monte-Carlo cross validation (MCCV) using balanced subsam-
pling where two thirds (2/3) of the samples were used to evaluate the feature importance. Sig-
nificant features were then used to build classification models that were validated on the
remaining 1/3 of the samples. The same procedure was repeated multiple times to calculate the
performance and confidence interval of each model.
Results and Discussion
A descriptive analysis of 28 blood metabolites and their correlation with HIV-1 infection is
shown in Table 1 (and S3 Fig). Unsupervised multivariate analysis using Heat Map (Fig 1) and
Randon Forest classification were also conducted between cases and controls. Results demon-
strated the existence of metabolites whose blood concentrations can clearly differentiate con-
trols from patients either on acute or chronic phases. The out of the box (OOB) error, after
5000 trees, is 0.0 according Random Forest classification.
Very low concentrations of sphingomyelins and dopamine in parallel with high levels of
dicarboxylicacylcarnitines, L-aspartate and many plasmalogen/plasminogen phosphatidylcho-
lines, such as PC ae C38:1 and PC ae C40:3, were detected in the blood of HIV-1-infected indi-
viduals compared with controls.
Table 1. The top 28 metabolites whose concentrations were statistically elevated or decreased in HIV patients compared to controls.
FDR = False Discovery Rate; C5-M-DC = Methylglutarylcarnitine; lysoPC a C24:0 = Glycerophospholipids; C5:1-DC = Glutaconylcarnitine; PC aa
C42:5 = Glycerophospholipids; lysoPC a C14:0 = Glycerophospholipids; PC aa C30:0 = Glycerophospholipids; Phosphatidylcholines PC aa
C28:1 = Glycerophospholipids; C12-DC = Dodecanedioylcarnitine; SM = Sphingomyelin.
Metabolite Correlation T test pValue FDR
PC ae C38:1 0.84706 10.205 8.0647E-13 1.9306E-5
C5-M-DC 0.84089 99.488 1.71E-08 2.01E-07
lysoPC a C24:0 0.82279 92.698 1.29E-07 1.44E-06
C5:1-DC 0.79126 82.856 2.69E-06 2.68E-05
Glutamate 0.71738 65.935 6.20E-04 5.58E-03
PC ae C40:3 0.57136 4.4578 6.2893E-5 1.082E-11
Aspartate 0.7492 72.427 7.50E-05 7.09E-04
PC aa C42:5 0.6687 57.588 9.53E-03 8.19E-02
SM C26:0 -0.57777 -4.5326 4.9721E-05 3.0639E-4
lysoPC a C14:0 -0.63814 -53.072 4.15E-02 3.14E-02
PC aa C30:0 -0.64955 -54.703 2.44E-02 1.92E-01
PC aa C28:1 -0.66539 -57.075 1.13E-03 9.26E-02
SM C26:1 -0.79524 -83.987 1.89E-06 1.99E-06
C12-DC -0.8409 -99.493 1.70E-08 2.01E-07
SM C20:2 -0.8444 -10.093 1.12E-08 1.51E-11
Nitrotyrosine -0.86159 -10.869 1.20E-10 1.75E-08
Dopamine -0.86968 -11.282 3.79E-11 5.97E-10
SM C18:1 -0.87877 -11.791 9.42E-11 1.62E-09
SM C18:0 -0.88526 -12.187 3.26E-12 6.15E-10
SM (OH) C16:1 -0.89156 -12.605 1.09E-11 2.28E-10
SM C16:0 -0.90533 -13.649 7.69E-13 1.82E-11
SM (OH) C24:1 -0.91078 -14.124 2.40E-13 6.49E-12
SM (OH) C14:1 -0.91275 -14.307 1.55E-13 4.88E-12
SM C24:1 -0.91696 -14.716 5.85E-14 2.21E-12
SM C16:1 -0.92619 -15.729 5.71E-15 2.70E-13
SM (OH) C22:1 -0.93876 -17.445 1.40E-16 8.83E-15
SM (OH) C22:2 -0.94566 -18.622 1.29E-17 1.22E-15
SM C24:0 -0.94912 -19.298 3.47E-19 6.56E-16
doi:10.1371/journal.pone.0161920.t001
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The severe deregulation in acylcarnitine and sphingomyelin metabolism suggests that HIV
infection leads to deficiencies in mitochondrial function. Therefore, we assembled ratios of
certain metabolite concentrations as proxies for enzymatic activity. We examined the propor-
tion of esterified to free carnitines, β- and O-oxidation, and the rate-limiting step in the uptake
of fatty acids into the mitochondria related to carnitine palmitoyl transferase I (CPT1) activity.
We also examined the SYNE2 locus because of its relation to SGPP1 (sphingosine-1-phosphate
phosphatase 1) activity, a key player in the sphingosine rheostat that governs the interchange
between pro-apoptotic ceramides and S1P, a well-established ligand in survival signaling[23].
ANOVA statistical analysis confirmed our hypothesis by demonstrating that HIV infection
is associated with a substantial deterioration in mitochondrial function. This conclusion is
supported by a decrease in the proportion between esterified and free carnitines ((Total esteri-
fied carnitines(AC)/ free carnitines (C0)) (p = 9.8245E-11 and False Discovery Rate (FDR) =
4.1977–10) (Fig 2A), decreased β-oxidation (p = 1.3529E-13 and FDR = 8.4782E-13) (Fig 2B)
in parallel with increased O-oxidation (p = 6.9445E-11 and FDR = 3.1085E-10) (Fig 2C),
and decreased uptake of fatty acids by the mitochondria (CPT1) (p = 0.0016126 and FDR =
0.0026136) (Fig 2F). As a consequence, the direct products of normal mitochondria, such as
non-essential amino acids (p = 1.5306E-47 and FDR = 7.1938E-46) (Fig 2D) and sphingomye-
lins (p = 1.1088E-18 and FDR = 6.74E-19) (Fig 2E) were down-regulated in patients with HIV
(Fig 2A to 2F). Disturbances in fatty acid oxidation (FAO), as revealed by declines in CPT1
and β-oxidation functions, were recently reported to be very important in T cell survival and
the promotion of CD8+ TM cell development[24]. Furthermore, it has been shown that per-
turbations on sphingolipids and glycerophospholipids altering membrane lipid composition
may impair innate immune responses.[25] As depicted in Fig 2B, β-oxidation is particularly
down-regulated (p = 2.5195E-8; FDR = 1.1412E-7) among INR.
Furthermore, there was a significant decline in sphingosine-1-phosphate phosphatase 1
activity (SGPP1, SYNE2 locus) after treatment, particularly among INR, when evaluated by the
Fig 1. Unsupervised Heat map Clustering Analysis depicting identification of metabolites able to
differentiate between Cases and Controls.
doi:10.1371/journal.pone.0161920.g001
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Fig 2. Proportion of Esterified to free Carnitines (Total AC/C0) (A; p = 9.8245E-11 and FDR = 4.1977–10),
Beta oxidation (B; p = 1.3529E-13 and FDR = 8.4782E-13) Omega Oxidation (C; p = 6.9445E-11 and FDR =
3.1085E-10), Non-Essential Amino acids other than Glu and Asp (D; p = 1.5306E-47 and FDR = 7.1938E-46),
sphingomyelin (E; p = 1.1088E-18 and FDR = 6.74E-19) and uptake of fatty acids to mitochondria (CPT1)
(F; p = 0.0016126 and FDR = 0.0026136). Y Axis is depicting micro molar plasma concentrations. Cont =
controls; Elite = elite controllers; RP = rapid progressors; IR = immunological responders;
INR = immunological non-responders.
doi:10.1371/journal.pone.0161920.g002
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ratio PC aa C28:1/PC ae C40:2 (p = 8.4667E-7, -log10(p) = 6.0723, FDR = 1.2712E-5) (Fig 3).
Importantly, Sphingosine-1-Phosphate (S1P) is involved in lymphocyte egress from lymphoid
organs[26, 27] and bone marrow[28, 29] into circulatory fluids via a gradient of S1P. Because
SGPP1 (SYNE2 Locus) is correlated to CD4+ T cell counts (p = 0.0071195; FDR = 0.16446, Fig
3), it is tempting to speculate the existence of a link between Sphingosine-1-Phosphate Phos-
phatase 1 activity and INR.
The amount of ether lipids as measured by the total acyl-alkyl-containing phosphatidylcho-
lines to total phosphatidylcholines (AGPS) ratio was down-regulated after 1 year of follow-up
in all groups but INR (p = 1.1405E-5, -log10(p) = 4.9429, FDR = 9.6586E-5, Fig 4). Because
ether lipids activate thymic and peripheral semi-invariant natural killer T cells known to be
evolutionarily conserved lipid reactive T cells, we hypothesized that the metabolic enzyme
alkylglycerone phosphate synthase (AGPS), a critical step in the synthesis of ether lipids, could
be aberrantly activated among INR, leading to impaired CD4+ T cell recovery. We therefore
evaluated ether lipid biosynthesis activity after treatment vis a vis viral load level and CD4/CD8
in all patients who naturally control viremia (Elite controllers) or Immunological Responders.
The results revealed a significant negative correlation (p = 8.5025E-7; FDR = 1.1053E-4) be-
tween Ether Lipids (AGPS) and increasing levels of CD4 (from 160 to 1215 mm3) (PostHoc =
160> 1215; 361> 1215), with opposite results observed for increases in viral load (p =
8.5025E-7 –Log10(p) = 4.9429, FDR = 1.1053E-4). In addition, the amount of ether lipids
remains elevated among INR even during periods of undetectable viral load (p = 1.1537E-4,
FDR = 3.5435E-4) when significant declines in SGPP1 (p = 1.0626E-20, FDR = 3.046E-19) and
in β-Oxidation (p = 3.3247E-5,FDR = 1.0212E-4) are also observed. Lipid alterations in HIV-
infected individuals receiving protease inhibitors based antiretroviral treatment determined
Fig 3. Histogram representing the mean Sphingosine-1-Phosphate Phosphatase 1 activity (ratio SGPP1) in different groups.
Sphingolipid metabolism is decreased in HIV patients compared to healthy controls (T Test = 0.012128) particularly in the INR group
after antiretroviral treatment (arrow) as demonstrated by the ANOVA analysis of SGPP1 activity (p = 2.5266E-7, -log10(p) = 6.5975,
FDR = 2.8123E-6). Y Axis is depicting micro molar plasma concentrations. Cont = controls; A1 and A2 are Elite controlers during recent
infection and after one year of enrollment; B1 and B2 = Rapid Progressors during recent infection and after one year of enrollment; C1 and
C2 = Immunologic Responders before treatment and after one year of treatment, D1 and D2 = INR before treatment and after one year of
treatment.
doi:10.1371/journal.pone.0161920.g003
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using untargeted metabolomic profiling of plasma, has been previously linked to markers of
inflammation, microbial translocation, and hepatic function, suggesting that dysregulated
innate immune activation and hepatic dysfunction are occurring among HIV antiretrovirally-
treated individuals[11]. Furthermore, metabolomic profile in HIV-infected children shows
hypoleptinemia and hypoadiponectinemia and is the activation of critical adipose tissue storage
and function in the adaptation to malnutrition[30]. Also, alterations in the Cerebrospinal fluid
metabolome among HIV antiretrovirally-treated individuals harboring HIV-associated neuro-
cognitive disorders reveal that persistent inflammation, glial responses, glutamate neurotoxicity,
and altered brain waste disposal are associated with cognitive alteration[31]. In the current
study, we did not assess markers for microbial translocation or the nutritional status of recruited
patients. We were not able to find any difference in the metabolomics profile between gender
and age, and this may be attributed to the small sample size of this study, since only 3 women
were included and only three individuals were over 50 years old out of 20 participants.
We investigated the presence of a metabolomic signature that can be used to identify
“Rapid Progression” and “INR” at baseline. As seen in S1 Fig, a combination of five different
metabolites and ratios were able to accurately identify Rapid Progressors or INR at baseline
with 88.89% sensitivity, 92.31% specificity, 88.89% positive predictive value and 92.31% nega-
tive predictive value (AUC = 0.871; 95% CI: 0.619–1; p = 0.01). During the discovery phase,
the results repeatedly pointed to metabolites and ratios linked to metabolism affecting acylcar-
nitine hydroxylation and carboxylation as well as the catabolism of branched chain amino
acids, lysine, organic acids, and tryptophan (Table 1). Notably, when elevated, as seen among
Elite controllers, these biochemical markers are highly suggestive of an inborn error of
Fig 4. Histogram representing the mean Ether lipid concentration in different groups. Ether lipid production returns to normal levels
after 1 year of follow-up except in the INR group (arrow, p = 1.1405E-5, -log10(p) = 4.9429, FDR = 9.6586E-5). Y Axis is depicting micro
molar plasma concentrations. Cont = controls; A1 and A2 are Elite controllers during recent infection and after one year of enrollment; B1
and B2 = Rapid Progressors during recent infection and after one year of enrollment; C1 and C2 = Immunologic Responders before
treatment and after one year of treatment; D1 and D2 = INR before treatment and after one year of treatment.
doi:10.1371/journal.pone.0161920.g004
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metabolism named late-onset multiple acyl-coenzyme A dehydrogenase deficiency (MADD,
MIM#231680)[32]. Therefore, we quantified the amount of organic acids, branched chain
amino acids and lysine as a diagnostic approach for MADD[32], in addition to using the ratio
C7-DC/C8 as a proxy to analyze the activity of a MADD related enzyme, electron-transferring
flavoprotein dehydrogenase (ETFDH). The results demonstrated increased levels of alpha ami-
noadipic acid (p = 0.029658, -log10(p) = 1.5279, FDR = 0.078855), lysine (p = 0.02768, -log10
(p) = 1.5578, FDR = 0.075369) and Branch Chain Amino Acids (BCAA) (p = 3.2721E-12,
-log10(p) = 11.485, FDR = 1.6189E-11) among Elite controllers. Moreover, the ETFDH activity
is significantly less active among Elite controllers compared to the other HIV-infected groups
(T-Test = 6.505E-4) and to HIV-uninfected controls (T-Test = 0.0092744). Therefore, possibly
an inborn error of metabolism (MADD) and its reduction of ETFDH activity, which can be
asymptomatic in many individuals, relates to a control of HIV replication and a functional
cure of HIV infection. In order to tease out if any metabolomics profile were related to antire-
troviral use, we compared the profile of samples from individuals under antiretroviral therapy
(last time point of immunological responders and IRN) with samples from other patients/time
points, and we have not been able to identify any specific signature that might be related to
antiretroviral use (data on file).
Suppressing HIV replication using antiretrovirals does not completely abrogate the acceler-
ated tissue and organ damage among HIV-infected individuals compared to HIV-uninfected
controls[33]. The results presented here make it clear that in addition to their utility as reliable
biomarkers, metabolomic profiles of HIV-infected individuals can provide insights into mech-
anisms of HIV-related tissue and organ damage, and further the development of interventional
strategies, such as fixing the decrease levels of dopamine seen among HIV-infected individuals
in this study. Of note, low dopamine levels have been implicated in the mechanisms of psychi-
atric diseases such as depression [34–36] and schizophrenia[37]. As an example and corrobo-
rating the predicative abilities of the metabolic signatures identified in blood collected at
baseline, of patients that years later developed specific HIV phenotypes, a recent study have
been able to identify functional annotations that accurately predicted the inflammatory
response of cells derived from patients suffering from inborn errors of metabolism solely on
their altered membrane lipid composition[25].
We recognize that further external validation with larger groups of patients is necessary to
consolidate the results presented here. Furthermore, metabolites among HIV-infected individ-
uals should also be adjusted by clinical manifestation, biochemistry parameters, cytokines pro-
files, cell activation, apoptosis and translocation markers, etc.
Conclusions
To the best of our knowledge, this is the first description of blood-based markers from metabo-
lomics showing a very high accuracy of discriminating HIV infection between a variety of con-
trols and also have the ability to predict rapid disease progression or poor antiretroviral
immunological response. These data suggest that the metabolites evaluated here can be used as
biomarkers of HIV natural evolution or treatment response and provide insight into the mech-
anisms of the disease.
Supporting Information
S1 Fig. Viral load and CD4+ T cell count linear regression from a period before 2 years of fol-
low up in elite controllers (Panel A) and rapid progressors (panel B).
(TIF)
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S2 Fig. PLS-DA and permutation testing analysis (p<5e-04 after 2000 permutations)
revealing clear differences between patients with HIV and controls.
(TIF)
S3 Fig. Comparison between the multivariate ROC curves obtained in training and valida-
tion sets using the 5 HIV predictive metabolites described in Table 1. The empirical p values
after 100 permutation rounds are also shown.
(TIF)
S1 File. Supplementary tables A and B.
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